ABSTRACT
Candidiasis [1] [3] (5%)
Carcinoma [2] [2] •
Cellulitis [1] (<5%)
[2] [5]
Dermatitis [1] • [3] [4]
Dermatomyositis [5] [4]
Diaphoresis • •
Eczema [2] [3]
Edema [3] (12%)
Erythema [1] • •
Erythema multiforme [1] • [2]
Erythema nodosum [1] [1]
Exanthems [2] [5]
Fixed eruption [1] [1] [1] [1]
Folliculitis [1] [2]
Granuloma annulare [1] [1]
Granulomas [1] [2] [1]
Granulomatous reaction [5] [5] [1]
Henoch-Schönlein purpura [1] [3]
Herpes simplex [1] [4] (10%)
[1]
Herpes zoster [6] [4] [8] [4]
Hypersensitivity [2] • [1] • [10] (11%)
[1]
Kaposi’s sarcoma [1] [1] [2]
Leprosy [1] [2] [1]
Lichen planus [2] [2]
A Adalimumab; C Certolizumab; E Etanercept; G Golimumab; I Infliximab; M Mycophenolate
A C E G I M =
Lichenoid eruption [3] [3] [3]
Lupus erythematosus [13] [24] [2] [31]
Lupus syndrome [1] • [1] [8]
Lymphadenopathy [1] • [1]
Lymphoma [6] • [2] [8]
Lymphoproliferative disease [1] [1]
Malignancies [1] [1] [5]
Melanoma [5] [2] [1] [1]
Morphea [1] [1]
Necrotizing fasciitis [1] [1]
Neoplasms [1] [1] [1] [2]
Nevi [1] [2]
Peripheral edema (<5%) [1] [1] [1] (29%)
Pruritus [3] [1] (2-5%)
[6] (7%)
[1]
Pseudolymphoma [1] [1] [2]
Psoriasis [32] [3] [19] • [48] (11%)
[1]
Pustules [1] [2] [6]
Rash [3] (12%)
• [7] (15%)
[3] [11] (25%)
[2] (8%)
Rosacea [1] [1] [1]
Sarcoidosis [4] [7] • [2]
Serum sickness • [4]
Squamous cell carcinoma [2] [3] [1] [1]
Stevens-Johnson syndrome [2] • [1]
Thrombocytopenic purpura [1] •
Toxic epidermal necrolysis • [1]
Tumors [1] [1]
Ulcerations • [1]
Urticaria [2] • [2] [6] (17%)
[1]
Vasculitis [7] (13%)
• [21] (25%)
• [14] (63%)
Vitiligo [2] [4]
HAIR
Alopecia [2] [1] [3] [3] [2]
A Adalimumab; C Certolizumab; E Etanercept; G Golimumab; I Infliximab; M Mycophenolate
A C E G I M =
Alopecia areata [6] [1] [3]
NAILS
Onycholysis [1] [1]
MUCOSAL
Gingivitis [1] (7%)
•
Oral candidiasis [1] (10%)
Oral ulceration [1] [5]
A Adalimumab; C Certolizumab; E Etanercept; G Golimumab; I Infliximab; M Mycophenolate
